Global health experts have warned that there could be a global health crisis in the loom, as drugs which was used to treat diseases such as malaria, tuberculosis and gonorrhea are increasingly becoming impotent. This is as a result of the fast growing resistance these parasites, viruses and bacteria that cause such diseases seem to gaining against pharmaceutical drugs.
Leading among them is gonorrhea, which according to the World Health Organisation (WHO) infect over 78 million people world wide. Making it the second most reported Sexually Transmitted Infection (STI) after chlamydia. Though gonorrhea can infect the rectum and genitals with glaring symptoms such as burning during urination and discharges from the urethra, many people can go diagnosed or untreated because not everybody experiences these symptoms.
The downside to untreated gonorrhea can cause complications, especially for women, who often do not experience any symptoms at all. This can increase the risk of contracting HIV or in most cases pelvic inflammatory disease, which can cause ectopic pregnancy or infertility. A pregnant woman with untreated gonorrhea, can infect her unborn child with the disease which can lead to blindness.
Another dangerous thing about gonorrhea is that it can lodge in a person’s throat undetected. It is believe that the microorganism can develop resistance from other bacteria that live in your throat, which has in the past been exposed to antibiotics. Experts say this could prove challenging since the practice of oral sex around the world is on the rise.
Are there any plans to develop a gonorrhea resistant drug? According to CNN health, the Global Antibiotic and Research Development Partnership together with Entasis Therapeutic, a US based biotech company developed a new antibiotic specifically made to target drug resistant gonorrhea.
“Zoliflodacin is a novel first-in-class oral antibiotic — in other words, a new and unique mechanism of potentially treating gonorrhea and is one of only three potential new antibiotic candidates currently undergoing trials. It had previously been put through clinical trials in 2015, but a lack of investment stopped the drug from progressing further.”
The Global Antibiotic Research and Development Partnership and Entasis is set to launch the final phase of trials of zoliflodacin this year. This will include 650 people in Thailand, South Africa, the USA and parts of Europe.
The drug, when approved by regulators will be registered in 2021 and made available on the market by 2023. It will also be introduced in low-middle income countries by he Global Antibiotic Research and Development Partnership with permission from Entasis.
Though measures are being put in place to ensure that the disease is checked, expects are still unsure whether the project will succeed not. That notwithstanding, they are committed to ensuring that the project falls through because of its significance to health.